This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Plaintiffs file second amended US antitrust complaint against Teva over EpiPen, Nuvigil

( October 29, 2024, 14:04 GMT | Official Statement) -- MLex Summary: Plaintiffs filed their second amended US class action complaint accusing Teva Pharmaceuticals of illegally conspiring to block access to generic versions of the EpiPen and the wakefulness drug Nuvigil. According to the complaint, Teva worked in secret to sign deals with two other pharmaceutical manufacturers — Mylan and Pfizer — that foreclosed generic competition to both the EpiPen and Nuvigil for several years longer than legally allowed.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections